Double Whammy For Acucela As Otsuka Ends Alliances
This article was originally published in PharmAsia News
Otsuka has terminated two licensing and development deals with Acucela in the wake of the recent Phase III failure of the US ophthalmic venture's lead pipeline molecule, prompting Acucela to delay its AGM and inversion plans.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.